Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 1999 Nov;24(5):413–430.

The prediction and prevention of Alzheimer's disease--towards a research agenda.

R van Reekum 1, M Simard 1, T Cohen 1
PMCID: PMC1189056  PMID: 10586533

Abstract

This paper sets a research agenda for the prediction and prevention of future onset of Alzheimer's disease (AD). From a MEDLINE review of the literature, the authors found age to be a predictor of AD. The literature also indicates that memory and attentional impairments predict AD, although the relative risk is relatively low. Late-onset depression may also predict AD, but these data are limited by a lack of cohort studies. Studying cognitively impaired subjects with late-onset depression may identify a high-risk group, facilitating prevention trials. Characteristics of an "ideal" preventive agent are suggested. There is a biologic rationale, and preliminary evidence, that non-steroidal anti-inflammatory drugs (including ASA), estrogen and vitamin E may play a preventive role in AD. Other compounds (such as acetylcholinesterase inhibitors) are also promising, but costs, side effects, and lack of other health benefits may preclude their use in all but very high-risk groups.

Full text

PDF
413

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexopoulos G. S., Meyers B. S., Young R. C., Mattis S., Kakuma T. The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry. 1993 Nov;150(11):1693–1699. doi: 10.1176/ajp.150.11.1693. [DOI] [PubMed] [Google Scholar]
  2. Alexopoulos G. S., Young R. C., Meyers B. S. Geriatric depression: age of onset and dementia. Biol Psychiatry. 1993 Aug 1;34(3):141–145. doi: 10.1016/0006-3223(93)90383-o. [DOI] [PubMed] [Google Scholar]
  3. Andersen K., Launer L. J., Ott A., Hoes A. W., Breteler M. M., Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology. 1995 Aug;45(8):1441–1445. doi: 10.1212/wnl.45.8.1441. [DOI] [PubMed] [Google Scholar]
  4. Bachman D. L., Wolf P. A., Linn R. T., Knoefel J. E., Cobb J. L., Belanger A. J., White L. R., D'Agostino R. B. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology. 1993 Mar;43(3 Pt 1):515–519. doi: 10.1212/wnl.43.3_part_1.515. [DOI] [PubMed] [Google Scholar]
  5. Baddeley A. D., Bressi S., Della Sala S., Logie R., Spinnler H. The decline of working memory in Alzheimer's disease. A longitudinal study. Brain. 1991 Dec;114(Pt 6):2521–2542. doi: 10.1093/brain/114.6.2521. [DOI] [PubMed] [Google Scholar]
  6. Baldereschi M., Di Carlo A., Lepore V., Bracco L., Maggi S., Grigoletto F., Scarlato G., Amaducci L. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 1998 Apr;50(4):996–1002. doi: 10.1212/wnl.50.4.996. [DOI] [PubMed] [Google Scholar]
  7. Berlinger W. G., Potter J. F. Low Body Mass Index in demented outpatients. J Am Geriatr Soc. 1991 Oct;39(10):973–978. doi: 10.1111/j.1532-5415.1991.tb04043.x. [DOI] [PubMed] [Google Scholar]
  8. Birge S. J. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc. 1996 Jul;44(7):865–870. doi: 10.1111/j.1532-5415.1996.tb03749.x. [DOI] [PubMed] [Google Scholar]
  9. Birge S. J. The role of estrogen in the treatment and prevention of dementia: introduction. Am J Med. 1997 Sep 22;103(3A):1S–2S. doi: 10.1016/s0002-9343(97)00263-5. [DOI] [PubMed] [Google Scholar]
  10. Bowen J., Teri L., Kukull W., McCormick W., McCurry S. M., Larson E. B. Progression to dementia in patients with isolated memory loss. Lancet. 1997 Mar 15;349(9054):763–765. doi: 10.1016/S0140-6736(96)08256-6. [DOI] [PubMed] [Google Scholar]
  11. Brayne C., Best N., Muir M., Richards S. J., Gill C. Five-year incidence and prediction of dementia and cognitive decline in a population sample of women aged 70-79 at baseline. Int J Geriatr Psychiatry. 1997 Nov;12(11):1107–1118. doi: 10.1002/(sici)1099-1166(199711)12:11<1107::aid-gps695>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  12. Breitner J. C., Gau B. A., Welsh K. A., Plassman B. L., McDonald W. M., Helms M. J., Anthony J. C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994 Feb;44(2):227–232. doi: 10.1212/wnl.44.2.227. [DOI] [PubMed] [Google Scholar]
  13. Breitner J. C., Welsh K. A., Helms M. J., Gaskell P. C., Gau B. A., Roses A. D., Pericak-Vance M. A., Saunders A. M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995 Jul-Aug;16(4):523–530. doi: 10.1016/0197-4580(95)00049-k. [DOI] [PubMed] [Google Scholar]
  14. Buschke H., Fuld P. A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974 Nov;24(11):1019–1025. doi: 10.1212/wnl.24.11.1019. [DOI] [PubMed] [Google Scholar]
  15. Bäckman L., Small B. J. Influences of cognitive support on episodic remembering: tracing the process of loss from normal aging to Alzheimer's disease. Psychol Aging. 1998 Jun;13(2):267–276. doi: 10.1037//0882-7974.13.2.267. [DOI] [PubMed] [Google Scholar]
  16. Caine E. D. Pseudodementia. Current concepts and future directions. Arch Gen Psychiatry. 1981 Dec;38(12):1359–1364. doi: 10.1001/archpsyc.1981.01780370061008. [DOI] [PubMed] [Google Scholar]
  17. Camicioli R., Howieson D., Lehman S., Kaye J. Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Neurology. 1997 Apr;48(4):955–958. doi: 10.1212/wnl.48.4.955. [DOI] [PubMed] [Google Scholar]
  18. Coen R. F., Maguire C., Swanwick G. R., Kirby M., Burke T., Lawlor B. A., Walsh J. B., Coakley D. Letter and category fluency in Alzheimer's disease: a prognostic indicator of progression? Dementia. 1996 Sep-Oct;7(5):246–250. doi: 10.1159/000106887. [DOI] [PubMed] [Google Scholar]
  19. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
  20. Dartigues J. F., Commenges D., Letenneur D., Barberger-Gateau P., Gilleron V., Fabrigoule C., Mazaux J. M., Orgogozo J. M., Salamon R. Cognitive predictors of dementia in elderly community residents. Neuroepidemiology. 1997;16(1):29–39. doi: 10.1159/000109668. [DOI] [PubMed] [Google Scholar]
  21. Davis R. E., Doyle P. D., Carroll R. T., Emmerling M. R., Jaen J. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering? Arzneimittelforschung. 1995 Mar;45(3A):425–431. [PubMed] [Google Scholar]
  22. Devanand D. P., Sano M., Tang M. X., Taylor S., Gurland B. J., Wilder D., Stern Y., Mayeux R. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry. 1996 Feb;53(2):175–182. doi: 10.1001/archpsyc.1996.01830020093011. [DOI] [PubMed] [Google Scholar]
  23. Diaz Brinton R., Yamazaki R. S. Advances and challenges in the prevention and treatment of Alzheimer's disease. Pharm Res. 1998 Mar;15(3):386–398. doi: 10.1023/a:1011963929012. [DOI] [PubMed] [Google Scholar]
  24. Doraiswamy P. M., Charles H. C., Krishnan K. R. Prediction of cognitive decline in early Alzheimer's disease. Lancet. 1998 Nov 21;352(9141):1678–1678. doi: 10.1016/S0140-6736(05)61449-3. [DOI] [PubMed] [Google Scholar]
  25. Doraiswamy P. M., Krishen A., Stallone F., Martin W. L., Potts N. L., Metz A., MRCPsych A. M., DeVeaugh-Geiss J. NSAIDs and cognition in Alzheimer's disease. Neurology. 1996 Apr;46(4):1194–1194. doi: 10.1212/wnl.46.4.1194. [DOI] [PubMed] [Google Scholar]
  26. Díaz-Olavarrieta C., Ostrosky-Solis F., Garcia de la Cadena C., Rodriguez Y., Alonso E. Neuropsychological changes in subjects at risk of inheriting Alzheimer's disease. Neuroreport. 1997 Jul 28;8(11):2449–2453. doi: 10.1097/00001756-199707280-00008. [DOI] [PubMed] [Google Scholar]
  27. Evans D. A., Beckett L. A., Field T. S., Feng L., Albert M. S., Bennett D. A., Tycko B., Mayeux R. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 1997 Mar 12;277(10):822–824. [PubMed] [Google Scholar]
  28. Fabrigoule C., Rouch I., Taberly A., Letenneur L., Commenges D., Mazaux J. M., Orgogozo J. M., Dartigues J. F. Cognitive process in preclinical phase of dementia. Brain. 1998 Jan;121(Pt 1):135–141. doi: 10.1093/brain/121.1.135. [DOI] [PubMed] [Google Scholar]
  29. Fillit H. Future therapeutic developments of estrogen use. J Clin Pharmacol. 1995 Sep;35(9 Suppl):25S–28S. doi: 10.1002/j.1552-4604.1995.tb04144.x. [DOI] [PubMed] [Google Scholar]
  30. Fillit H., Weinreb H., Cholst I., Luine V., McEwen B., Amador R., Zabriskie J. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 1986;11(3):337–345. doi: 10.1016/0306-4530(86)90019-3. [DOI] [PubMed] [Google Scholar]
  31. Flicker C., Ferris S. H., Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc. 1993 Oct;41(10):1029–1032. doi: 10.1111/j.1532-5415.1993.tb06448.x. [DOI] [PubMed] [Google Scholar]
  32. Flicker C., Ferris S. H., Reisberg B. A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease. J Geriatr Psychiatry Neurol. 1993 Apr-Jun;6(2):84–96. doi: 10.1177/089198879300600205. [DOI] [PubMed] [Google Scholar]
  33. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  34. Fox N. C., Warrington E. K., Freeborough P. A., Hartikainen P., Kennedy A. M., Stevens J. M., Rossor M. N. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain. 1996 Dec;119(Pt 6):2001–2007. doi: 10.1093/brain/119.6.2001. [DOI] [PubMed] [Google Scholar]
  35. Freedman M. Frontal and parietal lobe dysfunction in depression: delayed alternation and tactile learning deficits. Neuropsychologia. 1994 Aug;32(8):1015–1025. doi: 10.1016/0028-3932(94)90050-7. [DOI] [PubMed] [Google Scholar]
  36. Fuld P. A., Masur D. M., Blau A. D., Crystal H., Aronson M. K. Object-memory evaluation for prospective detection of dementia in normal functioning elderly: predictive and normative data. J Clin Exp Neuropsychol. 1990 Aug;12(4):520–528. doi: 10.1080/01688639008400998. [DOI] [PubMed] [Google Scholar]
  37. Giacobini E. Therapy of Alzheimer disease: symptomatic or neuroprotective? J Neural Transm Suppl. 1994;43:211–217. [PubMed] [Google Scholar]
  38. Gibaldi M. Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? J Clin Pharmacol. 1997 Dec;37(12):1087–1099. doi: 10.1002/j.1552-4604.1997.tb04292.x. [DOI] [PubMed] [Google Scholar]
  39. Graham J. E., Rockwood K., Beattie B. L., Eastwood R., Gauthier S., Tuokko H., McDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997 Jun 21;349(9068):1793–1796. doi: 10.1016/S0140-6736(97)01007-6. [DOI] [PubMed] [Google Scholar]
  40. Hachinski V. C., Iliff L. D., Zilhka E., Du Boulay G. H., McAllister V. L., Marshall J., Russell R. W., Symon L. Cerebral blood flow in dementia. Arch Neurol. 1975 Sep;32(9):632–637. doi: 10.1001/archneur.1975.00490510088009. [DOI] [PubMed] [Google Scholar]
  41. He J., Whelton P. K., Vu B., Klag M. J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998 Dec 9;280(22):1930–1935. doi: 10.1001/jama.280.22.1930. [DOI] [PubMed] [Google Scholar]
  42. Hebert L. E., Scherr P. A., Beckett L. A., Albert M. S., Pilgrim D. M., Chown M. J., Funkenstein H. H., Evans D. A. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995 May 3;273(17):1354–1359. [PubMed] [Google Scholar]
  43. Honjo H., Ogino Y., Naitoh K., Urabe M., Kitawaki J., Yasuda J., Yamamoto T., Ishihara S., Okada H., Yonezawa T. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem. 1989;34(1-6):521–525. doi: 10.1016/0022-4731(89)90137-4. [DOI] [PubMed] [Google Scholar]
  44. Howieson D. B., Dame A., Camicioli R., Sexton G., Payami H., Kaye J. A. Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. J Am Geriatr Soc. 1997 May;45(5):584–589. doi: 10.1111/j.1532-5415.1997.tb03091.x. [DOI] [PubMed] [Google Scholar]
  45. Hulette C. M., Welsh-Bohmer K. A., Murray M. G., Saunders A. M., Mash D. C., McIntyre L. M. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998 Dec;57(12):1168–1174. doi: 10.1097/00005072-199812000-00009. [DOI] [PubMed] [Google Scholar]
  46. Hänninen T., Soininen H. Age-associated memory impairment. Normal aging or warning of dementia? Drugs Aging. 1997 Dec;11(6):480–489. doi: 10.2165/00002512-199711060-00007. [DOI] [PubMed] [Google Scholar]
  47. Jacobs D. M., Sano M., Dooneief G., Marder K., Bell K. L., Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology. 1995 May;45(5):957–962. doi: 10.1212/wnl.45.5.957. [DOI] [PubMed] [Google Scholar]
  48. Johnson S. R. Menopause and hormone replacement therapy. Med Clin North Am. 1998 Mar;82(2):297–320. doi: 10.1016/s0025-7125(05)70608-8. [DOI] [PubMed] [Google Scholar]
  49. Jorm A. F., Christensen H., Korten A. E., Henderson A. S., Jacomb P. A., Mackinnon A. Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? A longitudinal study of an elderly community sample. Psychol Med. 1997 Jan;27(1):91–98. doi: 10.1017/s0033291796003923. [DOI] [PubMed] [Google Scholar]
  50. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., Sasaki H., Abe K., Iwatsubo T., Kosaka T. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998 Jul;44(1):17–26. doi: 10.1002/ana.410440108. [DOI] [PubMed] [Google Scholar]
  51. Kilander L., Ohrvall M. Alpha-tocopherol and Alzheimer's disease. N Engl J Med. 1997 Aug 21;337(8):572–573. [PubMed] [Google Scholar]
  52. Klockgether T., Weller M., Haarmeier T., Kaskas B., Maier G., Dichgans J. Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. Neurology. 1997 Jan;48(1):275–276. doi: 10.1212/wnl.48.1.275. [DOI] [PubMed] [Google Scholar]
  53. Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994 Apr 6;271(13):985–991. [PubMed] [Google Scholar]
  54. Knopman D., Schneider L., Davis K., Talwalker S., Smith F., Hoover T., Gracon S. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology. 1996 Jul;47(1):166–177. doi: 10.1212/wnl.47.1.166. [DOI] [PubMed] [Google Scholar]
  55. Kral V. A., Emery O. B. Long-term follow-up of depressive pseudodementia of the aged. Can J Psychiatry. 1989 Jun;34(5):445–446. doi: 10.1177/070674378903400515. [DOI] [PubMed] [Google Scholar]
  56. Kral V. A. The relationship between senile dementia (Alzheimer type) and depression. Can J Psychiatry. 1983 Jun;28(4):304–306. doi: 10.1177/070674378302800414. [DOI] [PubMed] [Google Scholar]
  57. Lichtman R. Perimenopausal and postmenopausal hormone replacement therapy. Part 1. An update of the literature on benefits and risks. J Nurse Midwifery. 1996 Jan-Feb;41(1):3–28. doi: 10.1016/0091-2182(95)00082-8. [DOI] [PubMed] [Google Scholar]
  58. Linn R. T., Wolf P. A., Bachman D. L., Knoefel J. E., Cobb J. L., Belanger A. J., Kaplan E. F., D'Agostino R. B. The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. Arch Neurol. 1995 May;52(5):485–490. doi: 10.1001/archneur.1995.00540290075020. [DOI] [PubMed] [Google Scholar]
  59. Lucca U., Tettamanti M., Forloni G., Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry. 1994 Dec 15;36(12):854–856. doi: 10.1016/0006-3223(94)90598-3. [DOI] [PubMed] [Google Scholar]
  60. Marcusson J., Rother M., Kittner B., Rössner M., Smith R. J., Babic T., Folnegovic-Smalc V., Möller H. J., Labs K. H. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):320–328. doi: 10.1159/000106650. [DOI] [PubMed] [Google Scholar]
  61. Masur D. M., Sliwinski M., Lipton R. B., Blau A. D., Crystal H. A. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology. 1994 Aug;44(8):1427–1432. doi: 10.1212/wnl.44.8.1427. [DOI] [PubMed] [Google Scholar]
  62. McBee W. L., Dailey M. E., Dugan E., Shumaker S. A. Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am. 1997 Jun;26(2):329–345. doi: 10.1016/s0889-8529(05)70250-4. [DOI] [PubMed] [Google Scholar]
  63. McGeer P. L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990 Apr 28;335(8696):1037–1037. doi: 10.1016/0140-6736(90)91101-f. [DOI] [PubMed] [Google Scholar]
  64. McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996 Aug;47(2):425–432. doi: 10.1212/wnl.47.2.425. [DOI] [PubMed] [Google Scholar]
  65. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  66. Morris J. C., Storandt M., McKeel D. W., Jr, Rubin E. H., Price J. L., Grant E. A., Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996 Mar;46(3):707–719. doi: 10.1212/wnl.46.3.707. [DOI] [PubMed] [Google Scholar]
  67. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J. 1994 Aug;41(4):361–371. doi: 10.1507/endocrj.41.361. [DOI] [PubMed] [Google Scholar]
  68. Paganini-Hill A., Henderson V. W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994 Aug 1;140(3):256–261. doi: 10.1093/oxfordjournals.aje.a117244. [DOI] [PubMed] [Google Scholar]
  69. Paganini-Hill A., Henderson V. W. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996 Oct 28;156(19):2213–2217. [PubMed] [Google Scholar]
  70. Persson G., Skoog I. Subclinical dementia: relevance of cognitive symptoms and signs. J Geriatr Psychiatry Neurol. 1992 Jul-Sep;5(3):172–178. doi: 10.1177/002383099200500307. [DOI] [PubMed] [Google Scholar]
  71. Pincus M. M. Alpha-tocopherol and Alzheimer's disease. N Engl J Med. 1997 Aug 21;337(8):572–573. doi: 10.1056/NEJM199708213370814. [DOI] [PubMed] [Google Scholar]
  72. Prince M., Rabe-Hesketh S., Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? An analysis based on data from the MRC treatment trial of hypertension in older adults. Neurology. 1998 Feb;50(2):374–379. doi: 10.1212/wnl.50.2.374. [DOI] [PubMed] [Google Scholar]
  73. Prince M., Rabe-Hesketh S., Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? An analysis based on data from the MRC treatment trial of hypertension in older adults. Neurology. 1998 Feb;50(2):374–379. doi: 10.1212/wnl.50.2.374. [DOI] [PubMed] [Google Scholar]
  74. Reding M., Haycox J., Blass J. Depression in patients referred to a dementia clinic. A three-year prospective study. Arch Neurol. 1985 Sep;42(9):894–896. doi: 10.1001/archneur.1985.04060080080019. [DOI] [PubMed] [Google Scholar]
  75. Reiman E. M., Caselli R. J., Yun L. S., Chen K., Bandy D., Minoshima S., Thibodeau S. N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996 Mar 21;334(12):752–758. doi: 10.1056/NEJM199603213341202. [DOI] [PubMed] [Google Scholar]
  76. Reisberg B., Ferris S. H., de Leon M. J., Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982 Sep;139(9):1136–1139. doi: 10.1176/ajp.139.9.1136. [DOI] [PubMed] [Google Scholar]
  77. Reynolds C. F., 3rd, Dew M. A., Frank E., Begley A. E., Miller M. D., Cornes C., Mazumdar S., Perel J. M., Kupfer D. J. Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry. 1998 Jun;155(6):795–799. doi: 10.1176/ajp.155.6.795. [DOI] [PubMed] [Google Scholar]
  78. Rich J. B., Rasmusson D. X., Folstein M. F., Carson K. A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995 Jan;45(1):51–55. doi: 10.1212/wnl.45.1.51. [DOI] [PubMed] [Google Scholar]
  79. Rodriguez M. M., Grossberg G. T. Estrogen as a psychotherapeutic agent. Clin Geriatr Med. 1998 Feb;14(1):177–189. [PubMed] [Google Scholar]
  80. Rogers J., Kirby L. C., Hempelman S. R., Berry D. L., McGeer P. L., Kaszniak A. W., Zalinski J., Cofield M., Mansukhani L., Willson P. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993 Aug;43(8):1609–1611. doi: 10.1212/wnl.43.8.1609. [DOI] [PubMed] [Google Scholar]
  81. Rogers J., Webster S., Lue L. F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging. 1996 Sep-Oct;17(5):681–686. doi: 10.1016/0197-4580(96)00115-7. [DOI] [PubMed] [Google Scholar]
  82. Rogers S. L., Friedhoff L. T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia. 1996 Nov-Dec;7(6):293–303. doi: 10.1159/000106895. [DOI] [PubMed] [Google Scholar]
  83. Rosen W. G., Mohs R. C., Davis K. L. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov;141(11):1356–1364. doi: 10.1176/ajp.141.11.1356. [DOI] [PubMed] [Google Scholar]
  84. Rozzini R., Ferrucci L., Losonczy K., Havlik R. J., Guralnik J. M. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc. 1996 Sep;44(9):1025–1029. doi: 10.1111/j.1532-5415.1996.tb02932.x. [DOI] [PubMed] [Google Scholar]
  85. Sachdev P. S., Smith J. S., Angus-Lepan H., Rodriguez P. Pseudodementia twelve years on. J Neurol Neurosurg Psychiatry. 1990 Mar;53(3):254–259. doi: 10.1136/jnnp.53.3.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Schmand B., Jonker C., Hooijer C., Lindeboom J. Subjective memory complaints may announce dementia. Neurology. 1996 Jan;46(1):121–125. doi: 10.1212/wnl.46.1.121. [DOI] [PubMed] [Google Scholar]
  87. Schneider L. S., Farlow M. R., Henderson V. W., Pogoda J. M. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 1996 Jun;46(6):1580–1584. doi: 10.1212/wnl.46.6.1580. [DOI] [PubMed] [Google Scholar]
  88. Schneider L. S., Tariot P. N. Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am. 1994 Jul;78(4):911–934. doi: 10.1016/s0025-7125(16)30142-0. [DOI] [PubMed] [Google Scholar]
  89. Schoeman J. H., Westaway M. S., Neethling A. The relationship between socioeconomic factors and pulmonary tuberculosis. Int J Epidemiol. 1991 Jun;20(2):435–440. doi: 10.1093/ije/20.2.435. [DOI] [PubMed] [Google Scholar]
  90. Schofield P. W., Marder K., Dooneief G., Jacobs D. M., Sano M., Stern Y. Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am J Psychiatry. 1997 May;154(5):609–615. doi: 10.1176/ajp.154.5.609. [DOI] [PubMed] [Google Scholar]
  91. Sherwin B. B. Estrogenic effects on memory in women. Ann N Y Acad Sci. 1994 Nov 14;743:213–231. doi: 10.1111/j.1749-6632.1994.tb55794.x. [DOI] [PubMed] [Google Scholar]
  92. Simard M., van Reekum R. Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Drugs Aging. 1999 Mar;14(3):197–230. doi: 10.2165/00002512-199914030-00004. [DOI] [PubMed] [Google Scholar]
  93. Small B. J., Herlitz A., Fratiglioni L., Almkvist O., Bäckman L. Cognitive predictors of incident Alzheimer's disease: a prospective longitudinal study. Neuropsychology. 1997 Jul;11(3):413–420. doi: 10.1037//0894-4105.11.3.413. [DOI] [PubMed] [Google Scholar]
  94. Sparks D. L., Liu H., Scheff S. W., Coyne C. M., Hunsaker J. C., 3rd Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol. 1993 Mar;52(2):135–142. doi: 10.1097/00005072-199303000-00006. [DOI] [PubMed] [Google Scholar]
  95. Speck C. E., Kukull W. A., Brenner D. E., Bowen J. D., McCormick W. C., Teri L., Pfanschmidt M. L., Thompson J. D., Larson E. B. History of depression as a risk factor for Alzheimer's disease. Epidemiology. 1995 Jul;6(4):366–369. doi: 10.1097/00001648-199507000-00006. [DOI] [PubMed] [Google Scholar]
  96. Steffens D. C., Plassman B. L., Helms M. J., Welsh-Bohmer K. A., Saunders A. M., Breitner J. C. A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Biol Psychiatry. 1997 Apr 15;41(8):851–856. doi: 10.1016/S0006-3223(96)00247-8. [DOI] [PubMed] [Google Scholar]
  97. Stewart W. F., Kawas C., Corrada M., Metter E. J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997 Mar;48(3):626–632. doi: 10.1212/wnl.48.3.626. [DOI] [PubMed] [Google Scholar]
  98. Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Finch C. E. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci. 1998 May 1;18(9):3180–3185. doi: 10.1523/JNEUROSCI.18-09-03180.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Thal L. J., Carta A., Doody R., Leber P., Mohs R., Schneider L., Shimohama S., Silber C. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11 (Suppl 3):46–49. [PubMed] [Google Scholar]
  100. Tierney M. C., Szalai J. P., Snow W. G., Fisher R. H., Nores A., Nadon G., Dunn E., St George-Hyslop P. H. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology. 1996 Mar;46(3):661–665. doi: 10.1212/wnl.46.3.661. [DOI] [PubMed] [Google Scholar]
  101. Van Duijn C. M., Clayton D. G., Chandra V., Fratiglioni L., Graves A. B., Heyman A., Jorm A. F., Kokmen E., Kondo K., Mortimer J. A. Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. Genet Epidemiol. 1994;11(6):539–551. doi: 10.1002/gepi.1370110609. [DOI] [PubMed] [Google Scholar]
  102. Wells C. E. Pseudodementia. Am J Psychiatry. 1979 Jul;136(7):895–900. doi: 10.1176/ajp.136.7.895. [DOI] [PubMed] [Google Scholar]
  103. Whitehead M. Treatments for menopausal and post-menopausal problems: present and future. Baillieres Clin Obstet Gynaecol. 1996 Sep;10(3):515–530. doi: 10.1016/s0950-3552(96)80028-9. [DOI] [PubMed] [Google Scholar]
  104. Wickelgren I. Estrogen stakes claim to cognition. Science. 1997 May 2;276(5313):675–678. doi: 10.1126/science.276.5313.675. [DOI] [PubMed] [Google Scholar]
  105. Yaffe K., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998 Mar 4;279(9):688–695. doi: 10.1001/jama.279.9.688. [DOI] [PubMed] [Google Scholar]
  106. de Leon M. J., Golomb J., George A. E., Convit A., Tarshish C. Y., McRae T., De Santi S., Smith G., Ferris S. H., Noz M. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol. 1993 Jul-Aug;14(4):897–906. [PMC free article] [PubMed] [Google Scholar]
  107. van Duijn C. M., Hofman A. Risk factors for Alzheimer's disease: the EURODEM collaborative re-analysis of case-control studies. Neuroepidemiology. 1992;11 (Suppl 1):106–113. doi: 10.1159/000111000. [DOI] [PubMed] [Google Scholar]
  108. van Reekum R., Black S. E., Conn D., Clarke D. Cognition-enhancing drugs in dementia: a guide to the near future. Can J Psychiatry. 1997 Jun;42 (Suppl 1):35S–50S. [PubMed] [Google Scholar]
  109. van Reekum R., Simard M., Clarke D., Binns M. A., Conn D. Late-life depression as a possible predictor of dementia: cross-sectional and short-term follow-up results. Am J Geriatr Psychiatry. 1999 Spring;7(2):151–159. [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES